Veru reports cancer drug has high potential to reduce Covid-19 deaths

Dr. Mitchell Steiner, chief executive of drugmaker Veru, said a Phase 2 trial of VERU-111 showed an 82% relative reduction in Covid-19 patient mortality versus placebo.
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.